Vitamin D Intake Associated With Basal Cell Carcinoma Risk
Oral vitamin D intake was associated with an increased risk for basal cell carcinoma, but not melanoma, according to two large cohort studies. (Source: CancerNetwork)
Source: CancerNetwork - September 4, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Skin Cancer (Nonmelanoma) Source Type: news
Featured Reviews: August 2016
An overview of the featured Cochrane Reviews for August 2016.Featured Review: Interventions to reduce corruption in the health sectorScarce evidence, but pointers to promising strategies to fight corruption in health care. Featured Review: Interventions for preventing abuse in theelderlyLack of good research on which programs or strategies are useful in preventing or reducing elder abuse. Featured Review: Music interventions for improving psychological and physical outcomes in cancer patientsAre there benefits of offering music interventions as a complementary treatment to people with cancer? Featured Review:...
Source: Cochrane News and Events - August 25, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news
Featured Review: Sun protection to prevent basal cell carcinoma and cutaneous squamous cell carcinoma of the skin
One randomised trial has been done to date that compares different ways of using sunscreen and physical barrier methods to protect against common non-melanoma skin cancers. The quality of evidence to date is low but the review team urge caution in changing behaviour on the basis of the review findings.Keratinocyte cancer is a more common but less serious type of skin cancer than melanoma. It comprises basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC). The main risk factor for keratinocyte cancer is exposure to ultraviolet radiation, which is a component of sunlight. The incidence of this type of cance...
Source: Cochrane News and Events - August 10, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news
Is Early Detection of Basal Cell Carcinoma Worthwhile? Is Early Detection of Basal Cell Carcinoma Worthwhile?
Could earlier detection of basal cell carcinoma reduce morbidity and health care costs? This review examines whether BCC fulfills the World Health Organization criteria for preventive screening.The British Journal of Dermatology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 8, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news
HedgePath reports positive interim data from Phase IIb trial of SUBA-Itraconazole to treat Gorlin Syndrome
US-based, clinical stage biopharmaceutical company HedgePath (HPPI) has reported positive interim data from its Phase IIb clinical trial of SUBA-Itraconazole to treat basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2016 Category: Pharmaceuticals Source Type: news
Giant Basal Cell Carcinoma of the Scalp Giant Basal Cell Carcinoma of the Scalp
A patient presents with a fungating giant basal cell carcinoma of the scalp. How was this tumor excised and reconstructed? < br / > < i > ePlasty, Open Access Journal of Plastic Surgery < /i > (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 21, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news
Giant Basal Cell Carcinoma of the ScalpGiant Basal Cell Carcinoma of the Scalp
A patient presents with a fungating giant basal cell carcinoma of the scalp. How was this tumor excised and reconstructed? ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Where did it all go wrong? Scientists identify 'cell of origin' in skin cancers
Scientists have identified for the first time the 'cell of origin' -- in other words, the first cell from which the cancer grows -- in basal cell carcinoma, the most common form of skin cancer, and followed the chain of events that lead to the growth of these invasive tumors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 8, 2016 Category: Science Source Type: news
Where did it all go wrong? Scientists identify 'cell of origin' in skin cancers
(University of Cambridge) Scientists have identified for the first time the 'cell of origin' -- in other words, the first cell from which the cancer grows -- in basal cell carcinoma, the most common form of skin cancer, and followed the chain of events that lead to the growth of these invasive tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2016 Category: Cancer & Oncology Source Type: news
After skin cancer surgery, careful reconstruction around eyes and nose
Treatment Terms
Plastic and reconstructive surgery
Skin cancers
Additional SEO Keywords
skin cancer surgery, basal cell carcinoma
SEO Meta Description
Facial reconstruction helped Elizabeth Ann Badgett return to normal after Mohs surgery to remove basal skin cancer from her lower eyelid, cheek and nose.
Overview
<p>For six months, Elizabeth Ann Badgett, of Clayton, NC, watched a painless, scaly spot appear and disappear on her nose. Each time the spot returned it was larger, until it reached the corner of her left eye. Her primary care doctor...
Source: dukehealth.org: Duke Health News - June 21, 2016 Category: Consumer Health News Authors: Anonymous Source Type: news
Topical skin creams effective to treat superficial basal cell carcinoma: New study
(Elsevier) Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services. Topical treatments are available for superficial basal cell carcinoma (BCC) but there has a lack of long-term follow-up data to guide treatment decisions. A three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2016 Category: Cancer & Oncology Source Type: news
Vismodegib in basal cell carcinoma: Added benefit not proven
(Institute for Quality and Efficiency in Health Care) The drug manufacturer presented no suitable data after expiry of the limitation period. A study on the comparator therapy, which was not presented, raised doubts about the added benefit of vismodegib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 27, 2016 Category: Global & Universal Source Type: news
Matrilin-2 protein distinguished BCCs from benign tumors in study
ORLANDO – Matrilin-2 – a matrix protein found in peritumoral stroma – reliably distinguished invasive basal cell carcinoma from the often difficult-to-distinguish basaloid follicular hamartoma (BFH), in a study that evaluated the protein as a marker in this setting.
The protein marked 41 of 42... (Source: Skin and Allergy News)
Source: Skin and Allergy News - May 23, 2016 Category: Dermatology Source Type: news
FDA approves Biofrontera’s drug-device combo for sun-induced skin cancer
Biofrontera (ETR:B8F) shares are up today after the said it won pre-market approval from the FDA for its drug-device combination treatment for a type of sun-induced skin cancer.
Leverkusen, Germany-based Biofrontera said the approval covers its Ameluz drug and BF-RhodoLED medical device for what it calls “photodynamic therapy” to treat mild to moderate actinic keratosis of the face and scalp.
Also known as solar keratosis, actinic keratosis is caused by damage to the skin by the sun’s ultraviolet rays. The Biofrontera treatment uses the Ameluz gel, which contains a photo-activated compound called 5-am...
Source: Mass Device - May 13, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Food & Drug Administration (FDA) Oncology Regulatory/Compliance Biofrontera Source Type: news
EZH2 potential target in cutaneous basal cell carcinoma
The expression of the histone methyltransferase EZH2 correlates with aggressive subtypes of cutaneous basal cell carcinoma, highlighting the possibility that EZH2 may be an actionable target in this malignancy, say researchers. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
